The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong financial foundations is crucial for investors seeking value beyond established names. Penny stocks, often representing smaller or newer companies, remain an intriguing investment area despite their somewhat outdated label; they can offer surprising opportunities when backed by solid balance sheets and potential for long-term growth.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ATRenew (RERE)	$4.38	$998.2M	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$2.15	$385.32M	✅ 3 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.33	$1.42B	✅ 4 ⚠️ 1 View Analysis >
FinVolution Group (FINV)	$4.95	$1.29B	✅ 4 ⚠️ 1 View Analysis >
Tuniu (TOUR)	$0.63	$84.58M	✅ 2 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$188.31M	✅ 4 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.47	$358.71M	✅ 3 ⚠️ 1 View Analysis >
LifeVantage (LFVN)	$4.04	$53.52M	✅ 4 ⚠️ 3 View Analysis >
SIGA Technologies (SIGA)	$7.80	$372.55M	✅ 2 ⚠️ 1 View Analysis >

Here's a peek at a few of the choices from the screener.

AC Immune (ACIU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: AC Immune SA is a clinical stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $267.84 million.

Operations: The company's revenue is derived from its segment focused on discovering and developing therapeutic and diagnostic products, generating CHF 3.57 million.

Market Cap: $267.84M

AC Immune's recent advancements in neurodegenerative disease diagnostics, particularly with its PET tracer ACI-19626, highlight its potential within the biotech sector. Despite being pre-revenue with CHF 3.57 million in revenue and a net loss of CHF 70.45 million, the company remains debt-free and has sufficient cash runway for over a year. While unprofitable, AC Immune has reduced losses over five years and maintains a seasoned management team. The company's innovative approach to targeting proteinopathies positions it competitively despite challenges like limited revenue streams and ongoing clinical trials impacting financial stability.

Codexis (CDXS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Codexis, Inc. offers technology solutions for therapeutics manufacturing using its proprietary CodeEvolver platform to create and commercialize novel enzymes across various global markets, with a market cap of approximately $171.74 million.

Operations: The company generates revenue from its biotechnology segment, amounting to $70.39 million.

Market Cap: $171.74M

Codexis, Inc. has demonstrated potential in the biotechnology sector with its proprietary CodeEvolver platform, generating US$70.39 million in revenue for 2025. While unprofitable with a net loss of US$43.97 million, the company shows signs of financial prudence as short-term assets exceed liabilities and cash reserves surpass debt levels. Recent agreements to produce siRNA material for pharmaceutical clients highlight its expanding capabilities in therapeutics manufacturing. However, challenges persist due to high share price volatility and an inexperienced management team averaging 1.2 years tenure, which may impact strategic execution despite forecasts of revenue growth up to US$76 million for 2026.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment in the United States, with a market cap of $202.11 million.

Operations: The company generates revenue of $149.5 million from its activities in developing and commercializing monoclonal antibody-based therapeutics.

Market Cap: $202.11M

MacroGenics, Inc., with a market cap of US$202.11 million, is focused on antibody-based cancer therapeutics and reported a revenue of US$149.5 million for 2025. Despite being unprofitable with a net loss of US$74.62 million, it has reduced losses by 25% annually over five years and remains debt-free. Its short-term assets exceed both short- and long-term liabilities, providing financial stability amidst high share price volatility. The recent FDA partial clinical hold on its LINNET study due to safety concerns adds uncertainty to its pipeline progress, while an experienced board offers governance stability in this challenging environment.

Key Takeaways

• Reveal the 360 hidden gems among our US Penny Stocks screener with a single click here.
• Seeking Other Investments? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.